

PRESS RELEASE



Active Biotech AB accepts offer from Carl Bennet AB on shares in Lifco AB

The Board of Active Biotech AB has decided to accept Carl Bennet AB's public offer on shares in Lifco AB at the price of 42 SEK per share.

The shares will be transferred in accordance with the offer.

Active Biotech's shareholding amounts to 1 812 103 Lifco serie B, corresponding to 19,9% of the capital and 12,5% of the votes.

The stockholding is a financial asset and a capital gain of 11,0 MSEK will arise upon sale.

Lund 2 August 2000

Active Biotech AB (publ)

Sven Andréasson
President & CEO

Active Biotech AB is a Swedish biotechnology company focused on the research and development of pharmaceuticals and vaccines, the core competence being knowledge of the human immune system. Active Biotech has a high quality project portfolio and considerable financial resources. Important products and projects include Dukoral, SBL Cholera Vaccine, a vaccine against tourist diarrhoea (ETEC), innovative drugs against MS (SAIK) and cancer (TTS). The turnover of Active Biotech was SEK 267 million in 1999.

Active Biotech AB
Box 724, S-220 07 Lund, Sweden
Tel +46 46-19 20 00
Fax +46 46 19 20 50
E-mail info@activebiotech.com



www.activebiotech.com